DMAC - Rega marang dodolan DiaMedica Therapeutics Inc

Simbol lan logo merek DiaMedica Pharma (DMAC)

DiaMedica Therapeutics (DMAC) is optimizing costs through international trial outsourcing to accelerate the market launch of its unique DM199 drug for ischemic stroke. The business valuation based on P/S according to the GURU.Markets chart indicates that the mark is a current metric. The company is implementing recombinant proteins to restore blood flow, preventing tissue destruction in severe kidney and brain pathologies.

DMAC (DiaMedica Therapeutics Inc.) riwayat Multiplikator P/S saka 04.07.2022 nganti 16.11.2026

Rincian metrik lan analitis perusahaan diamedica.com (DMAC)

- kuotasi saiki lan rata-rata prakiraan nilai:
Analisis umum perusahaan:DMAC - DiaMedica Therapeutics Inc.
Produk mawa merek DiaMedica Therapeutics

For the biopharmaceutical business of DiaMedica Therapeutics (DMAC), which targets the neurology market and blood flow restoration, P/S volatility reflects market expectations regarding the commercialization of stroke therapy. This ratio compares the company's market value to its annual sales volume, demonstrating the price of one ruble of revenue; excessive growth in this metric signals an overvaluation of the asset, creating risks in the event of any failures in strategy execution.